Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M
Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 million. The...
Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study
Generate:Biomedicines Announces Close of $273M Series C Financing
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
EBR Systems' Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results
Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement